We are live on ! Find out more
ADVM icon

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Adverum Biotechnologies in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

67.07% less ownership

Funds ownership: 67.07% → 0% (-67%)

100% less funds holding

Funds holding: 50 → 0 (-50)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $63.8M

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 50

Holders
–
Holders Change
-50
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
50
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$13.9M
2
PWA
Principia Wealth Advisory
Texas
-$9.41M
3
Frazier Life Sciences Management
Frazier Life Sciences Management
California
-$9.41M
4
TCG Crossover Management
TCG Crossover Management
California
-$7.56M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3.95M

ADVM Hedge Fund Activity: Q4 2025 in Review

0 of the 8,288 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2025, worth a combined $0 — down 100% from $63.8M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of ADVM and 0 opened new positions — a net loss of 50 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BML Capital Management, exiting entirely with an estimated $13.9M sold.

  • 0 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2025, down from 50 in Q3 2025.
  • Funds reported $0 of Adverum Biotechnologies stock for Q4 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Adverum Biotechnologies positions in Q4 2025 and 50 closed out, a net change of -50 holders.
  • The largest Adverum Biotechnologies seller in Q4 2025 was BML Capital Management, an estimated $13.9M sold.

Based on aggregated 13F filings for Q4 2025.